The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry

L.J.H. Brada*, M.S. Walma, R.M. van Dam, J. de Vos-Geelen, I.H. de Hingh, G.J. Creemers, M.S. Liem, L.J. Mekenkamp, V.E. de Meijer, D.J.A. de Groot, G.A. Patijn, J.W.B. de Groot, S. Festen, E.D. Kerver, M.W.J. Stommel, M.R. Meijerink, K. Bosscha, J.F. Pruijt, M.B. Polee, J.A. RopelaG.A. Cirkel, M. Los, J.W. Wilmink, N.H. Mohammad, H.C. van Santvoort, M.G. Besselink, I.Q. Molenaar*, Dutch Pancreatic Canc Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)


Background: The treatment options for patients with locally advanced pancreatic cancer (LAPC) have improved in recent years and consequently survival has increased. It is unknown, however, if elderly patients benefit from these improvements in therapy. With the ongoing aging of the patient population and an increasing incidence of pancreatic cancer, this patient group becomes more relevant. This study aims to clarify the association between increasing age, treatment and overall survival in patients with LAPC.Methods: Post-hoc analysis of a multicenter registry including consecutive patients with LAPC, who were registered in 14 centers of the Dutch Pancreatic Cancer Group (April 2015-December 2017). Patients were divided in three groups according to age (<65, 65-74 and >= 75 years). Primary outcome was overall survival stratified by primary treatment strategy. Multivariable regression analyses were performed to adjust for possible confounders.Results: Overall, 422 patients with LAPC were included; 162 patients (38%) aged <65 years, 182 patients (43%) aged 65-74 and 78 patients (19%) aged >= 75 years. Chemotherapy was administered in 86%, 81% and 50% of the patients in the different age groups (p<0.01). Median overall survival was 12, 11 and 7 months for the different age groups (p<0.01). Patients treated with chemotherapy showed comparable median overall survival of 13, 14 and 10 months for the different age groups (p=0.11). When adjusted for confounders, age was not associated with overall survival.Conclusion: Elderly patients are less likely to be treated with chemotherapy, but when treated with chemotherapy, their survival is comparable to younger patients. (C) 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.
Original languageEnglish
Pages (from-to)163-169
Number of pages7
Issue number1
Publication statusPublished - 1 Jan 2021


  • adenocarcinoma
  • age
  • best supportive care
  • chemotherapy
  • comorbidity
  • disparities
  • elderly
  • folfirinox
  • gemcitabine
  • locally advanced pancreatic cancer
  • nab-paclitaxel
  • older patients
  • outcomes
  • Best supportive care
  • AGE
  • Chemotherapy
  • Locally advanced pancreatic cancer
  • Elderly

Cite this